Finally, PTEN mutations promote MAPK pathway dependency in breast cancer [78]; the combination of PI3K and MEK inhibitors have been shown to improve responses to HER2+ gastric cancer [79], and future research is needed to determine if this combination could improve outcomes in patients with HER2+ breast cancer. Here, PTEN is linked to breast carcinoma.